Table 2 Occurrence of Chlamydia in a HIV population in relation to antiretroviral treatment
Treatment | Count | Chlamydia positive (%) | Statistics (χ2, P value) | OR (odd ratio and 95 % confidence interval) |
|---|---|---|---|---|
Not on ARV | 84 | 32 (38.1) | χ2 = 2.365, P = 0.124 | OR 0.649, 95 % CI 0.374–1.228 |
On ARV | 133 | 37 (27.8) | ||
Zidovudine | 12 | 6 (50) | χ2 = 3.158, P = 0.076 | OR 2.871, 95 % CI 0.861–9.562 |
Efavirenz | 114 | 29 (25.4) | χ2 = 2.784, P = 0.095 | OR 0.426, 95 % CI 0.154–1.184 |
Lamivudine | 129 | 36 (27.9) | χ2 = 0.043, P = 0.836 | OR: 0.774, 95 % CI 0.068–8.804 |
Tenofovir | 42 | 11 (26.2) | χ2 = 0.103, P = 0.748 | OR 0.873, 95 % CI 0.383–1.993 |
Nevirapine | 15 | 7 (46.7) | χ2 = 2.914, P = 0.088 | OR 0.426, 95 % CI 0.154–1.184 |
Stavudine | 81 | 23 (28.4) | χ2 = 0.014, P = 0.906 | OR 1.048, 95 % CI 0.479–2.291 |